Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Kidney Int. 2012 Mar;81(5):434-41. doi: 10.1038/ki.2011.399. Epub 2011 Dec 7.
Membranoproliferative glomerulonephritis (MPGN) denotes a general pattern of glomerular injury that is easily recognized by light microscopy. With additional studies, MPGN subgrouping is possible. For example, electron microscopy resolves differences in electron-dense deposition that are classically referred to as MPGN type I (MPGN I), MPGN II, and MPGN III, while immunofluorescence typically detects immunoglobulins in MPGN I and MPGN III but not in MPGN II. All three MPGN types stain positive for complement component 3 (C3). Subgrouping has led to unnecessary confusion, primarily because immunoglobulin-negative MPGN I and MPGN III are more common than once recognized. Together with MPGN II, which is now called dense deposit disease, immunoglobulin-negative, C3-positive glomerular diseases fall under the umbrella of C3 glomerulopathies (C3G). The evaluation of immunoglobulin-positive MPGN should focus on identifying the underlying trigger driving the chronic antigenemia or circulating immune complexes in order to begin disease-specific treatment. The evaluation of C3G, in contrast, should focus on the complement cascade, as dysregulation of the alternative pathway and terminal complement cascade underlies pathogenesis. Although there are no disease-specific treatments currently available for C3G, a better understanding of their pathogenesis would set the stage for the possible use of anti-complement drugs.
膜增生性肾小球肾炎 (MPGN) 表示一种易于通过光学显微镜识别的肾小球损伤的一般模式。通过进一步的研究,可能对 MPGN 进行亚组分类。例如,电子显微镜可以分辨出经典的 MPGN I、MPGN II 和 MPGN III 中电子致密沉积物的差异,而免疫荧光通常可以在 MPGN I 和 MPGN III 中检测到免疫球蛋白,但在 MPGN II 中则不能。所有三种 MPGN 类型均对补体成分 3 (C3) 呈阳性染色。亚组分类导致了不必要的混淆,主要是因为免疫球蛋白阴性的 MPGN I 和 MPGN III 比以前认为的更为常见。与现在称为致密沉积物病的 MPGN II 一起,免疫球蛋白阴性、C3 阳性的肾小球疾病归入 C3 肾小球病 (C3G) 的范畴。免疫球蛋白阳性的 MPGN 的评估应侧重于确定导致慢性抗原血症或循环免疫复合物的潜在触发因素,以便开始针对特定疾病的治疗。相比之下,C3G 的评估应侧重于补体级联反应,因为替代途径和末端补体级联反应的失调是发病机制的基础。尽管目前尚无针对 C3G 的特异性治疗方法,但对其发病机制的更好理解将为可能使用抗补体药物奠定基础。